Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Acalabrutinib + AZD4320 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD4320 | AZD 4320|AZD-4320 | BCL-XL inhibitor 14 BCL2 inhibitor 27 | AZD4320 inhibits BCL2 and BCL-XL, potentially resulting induction of tumor cell apoptosis and decreased tumor cell viability and tumor growth (PMID: 32988967). | |
Acalabrutinib | Calquence | ACP-196 | BTK inhibitor 38 | Calquence (acalabrutinib) selectively inhibits BTK, resulting in decreased B-cell receptor signaling, and potentially leading to decreased tumor cell proliferation (PMID: 27903679, PMID: 26957112). Calquence (acalabrutinib) is FDA approved for use in patients with mantle cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, and in combination with Treanda (bendamustine) and Rituxan (rituximab) in patients with untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|